Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Multi-camera autonomous robotic cameramen at the fingertips of all live video productions (Multi RoboDOP)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Switzerland
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2018)
Start date: 2018-12-01
End date: 2019-03-31
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Inconsistent quality, high personnel costs and personnel administration are the main bottlenecks faced by video production/technology companies. As a result, they experience very tight budgets (production requests to do “more with less” - nothing creative is left to do) and margin squeeze in case of production overruns (video productions often risk zero profit once overtime and overhead for human operators is factored in). Based on that, several industry players argue that 50% of the production requests are economically infeasible. To that direction, automation (applying artificial intelligence and robotics to replace repetitive and routine tasks) has emerged as a solution towards tackling the aforementioned challenges. That way, tasks are executed more efficiently and companies can remove economic bottlenecks, decrease mistakes, speed up output and devote more time to creative activities. However state-of-the-art automation technologies are limited to assistive systems or partial automation. Multi RoboDOP revolutionizes the video production industry, offering full automation. By extending the offerings of our patented single camera solution (RoboDOP), multi-camera robot setups (hardware) collaborate with our proprietary automation control software handling all operational tasks of traditional production crews autonomously. Not only do we make autonomous video production possible, but disrupt the cost structure of today’s video productions by reducing production costs by 40%. Thus we unlock 50% of the market that cannot afford professional video productions while offering reduced costs and increased ROIs for the remaining applications/use cases. Multi RoboDOP will need an additional investment for developing the multi-camera coordination software platform to enable future automation features involving multiple coordinated robots and expand our add-on workflow services such as post-production, cloud back-up/distribution and automated editing.

Keywords: video production,multi camera robots,level 5 automation full automation,multi camera coordination software,40 costs reduction,new market segments
BIOPRINTING BY LIGHT-SHEET LITHOGRAPHY: ENGINEERING COMPLEX TISSUES WITH HIGH RESOLUTION AT HIGH SPEED (BRIGHTER)

Framework: Horizon 2020 — Excellent Science
Programme: Future and Emerging Technologies (FET)
Theme: EIC Pathfinder
Destination: Novel ideas for radically new technologies
Action type: Research and Innovation actions
Countries involved: Germany,Spain,Israel,Germany,Sweden
Call: FET-Open Challenging Current Thinking (H2020-FETOPEN-2018-2019-2020-01, 2018)
Start date: 2019-07-01
End date: 2022-12-31
Duration (months): 42.0
Total project cost (EUR): 3520720.5
EU funding (EUR): 3459052.5
Participants: 6
Project status: SIGNED

Engineered tissues are key elements in both in vitro and in vivo applications, strongly impacting the academy, pharma and clinical sectors. Bioprinting is considered the most promising method to produce such engineered tissues. However, current bioprinting methods are severely limited by both insufficient speed and spatial resolution. Long printing times decrease cell viability, while poor spatial resolution fails to recreate the heterogeneous nature of native tissues. BRIGHTER will develop a new bioprinting technology able to produce tissue surrogates with high spatial resolution at high printing speed using an original top-down lithography approach, in contrast with current bottom-up, layer-by-layer bioprinting methods. BRIGHTER will combine high-speed light-sheet illumination and high-resolution digital photomasks to selectively photocrosslink cell-laden hydrogels in confined voxels and produce three-dimensional complex geometries. This process will enable the bioprinting of key anatomical microfeatures of tissue such as invaginations, evaginations or wavy morphologies. It will also incorporate hollow vascular structures while maintaining tissue mechanical integrity without the need of additional sacrificial material. As a remarkable feature, matrix crosslinking density can be fine-tuned using BRIGHTER’s approach, allowing the fabrication of cellular compartments requiring specific matrix stiffness such as stem cell niches. The proof-of-concept application will be bioprinting viable engineered skin tissues exploiting the key features of the BRIGHTER device: skin appendix (hair follicles, sweat glands), stem cell niches and a vascular network. The ultimate goal is to provide a superior alternative to state-or-the art 3D bioprinting with a disruptive bioprinting technology that would create new scientific and business opportunities.

Keywords: light sheet lithography,complex tissues,biofabrication,bioprinting,skin models,hydrogels,bioink
Novel avenues of action for a hallmark disordered protein of Parkinson's disease (SYN-CHARGE)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Denmark
Call: Individual Fellowships (H2020-MSCA-IF-2020, 2020)
Start date: 2022-02-01
End date: 2024-01-31
Duration (months): 24.0
Total project cost (EUR): 219312.0
EU funding (EUR): 219312.0
Participants: 1
Project status: SIGNED

Alpha-synuclein (aSN) is an intrinsically disordered protein (IDP) expressed by neurons, and well-known to aggregate in so-called Lewy bodies (LB) that are a hallmark of Parkinson’s disease (PD) and other LB disorders. Despite extensive research, the mechanisms underlying its toxicity in these disorders still remains to be understood. In this project, I will determine whether aSN can interact with other disordered proteins in a novel, mean-field type interaction, focusing on the disordered loop of the neuronal plasma membrane Ca2+ ATPase (PMCA). I will study this using biophysical techniques, in particular NMR, ITC and SAXS/SANS. This project will improve the understanding of aSN and its interactions and has the potential to pave the way for new discoveries, especially in drug design. I will gain important experience in project design and management, a research network in Europe, and take a significant step towards independence. I will undertake this project at the University of Copenhagen in the research group of Professor Birthe B. Kragelund, an expert in the field of IDP research. The Kragelund group has recently joined the BRAINSTRUC Consortium: a group of researchers working on the structural characterization of neuronal proteins. Thus, they required a postdoctoral researcher with a strong background in neuroscience and structural biology. I was uniquely qualified to take this position as I have been working on neurodegenerative proteins for several years and structurally characterized the IDP associated with Huntington’s disease. Professor Kragelund has experience supervising productive postdoctoral researchers, an extensive European network, and has access to the state-of-the-art facilities necessary to complete this project. I have recently acquired preliminary data to indicate that the two proteins (aSN and PMCA) interact directly. This project has the potential to change how we understand proteins associated with neurodegeneration and their interactions.

Keywords: intrinsically disordered proteins,idps
Distinctive characterization of regulatory plasma cells and pro-inflammatory B cells in immunity: their origins, molecular properties, and cellular fates. (PREG-LAB)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Immunity, Infection and Immunotherapy
Panel description: The immune system, related disorders and their mechanisms, biology of infectious agents and infection, biological basis of prevention and treatment of infectious diseases, innovative immunological tools and approaches, including therapies
Countries involved: Germany,France
Call: ERC Consolidator Grant (ERC-2014-CoG, 2014)
Start date: 2016-01-01
End date: 2021-12-31
Duration (months): 72.0
Total project cost (EUR): 1999375.0
EU funding (EUR): 1919811.06
Participants: 2
Project status: CLOSED

B cells can act both as negative regulators and as drivers of immunity through the production of cytokines. Through secretion of interleukin (IL)-10 B cells inhibited immunity in autoimmune and infectious diseases. For instance, IL-10 from B cells drove complete recovery from disease in experimental autoimmune encephalomyelitis (EAE), the primary animal model for multiple sclerosis (MS), while a lack of IL-10 production by B cells resulted in a severe chronic EAE. B cells can also suppress immunity via IL-35. Human B cells might similarly play inhibitory roles. In few patients with immune-mediated diseases B cell depletion therapy with Rituximab was associated with exacerbation of symptoms, or onset of new pathologies. Conversely, an opposite role of B cells as drivers of immunity was highlighted by the beneficial effect of Rituximab in some patients with rheumatoid arthritis or MS. Clinical improvement often precedes reduction in autoantibody levels in Rituximab treated patients, indicating that B cell-mediated pathogenesis is largely antibody-independent. A candidate factor for the deleterious effects of B cells in MS is IL-6. IL-6 secretion is a major mechanism of B cell-mediated pathogenesis in EAE, and B cells from MS patients produced more IL-6 than cells from healthy individuals. There is now an urgent need for the characterization of the phenotypes of the B cells producing IL-6, IL-10, and IL-35 in vivo at single cell and molecular levels. Markers for these cells might allow understanding the paradoxical effects of B cell-depletion therapy, and guide the development of novel agents depleting distinctively pro-inflammatory B cells, while sparing the remaining of the B cell compartment. Using advanced genetic models to identify and track cytokine-expressing cells, our project aims at characterizing B cells with pro- and anti-inflammatory functions in mice in vivo, to subsequently guide the identification of comparable markers in human.

Keywords: b cell,il 10,il 35,plasma cell,autoimmunity
YOUNGatHEART: CARDIAC REJUVENATION BY EPIGENETIC REMODELLING (YOUNGatHEART)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Physiology in Health, Disease and Ageing
Panel description: Organ and tissue physiology, comparative physiology, physiology of ageing, pathophysiology, interorgan and tissue communication, endocrinology, nutrition, metabolism, interaction with the microbiome, non-communicable diseases including cancer (and except disorders of the nervous system and immunity-related diseases)
Countries involved: Spain
Call: ERC Consolidator Grant (ERC-2014-CoG, 2014)
Start date: 2015-11-01
End date: 2020-10-31
Duration (months): 60.0
Total project cost (EUR): 1861910.0
EU funding (EUR): 1861910.0
Participants: 1
Project status: CLOSED

Aging poses the largest risk for cardiovascular disease (CVD) and is orchestrated, to some extent, by epigenetic changes. Despite the significant progress on many fronts in the cardiovascular field, non-inherited epigenetic regulation in cardiac aging and CVD remains unexplored. Dilated Cardiomyopathy (DCM) is a major contributor to healthcare costs and it is the leading indication for heart transplantation. We have recently discovered that adult cardiac-specific deletion of epigenetic regulator Bmi1 in mice induces DCM and heart failure. These unprecedented data support the idea that inadequate epigenetic regulation in adulthood is critical in CVD. In addition, our studies with parabiotic pairing of healthy and DCM-diagnosed mice show that the circulation of a healthy mouse significantly improve the cardiac performance of mouse with DCM. These ground-breaking discoveries suggest that DCM regression, or cardiac rejuvenation, is feasible in terms of epigenetic states. Therefore, YOUNGatHEART will unveil significant breakthrough on (1) how non-inherited epigenetic deregulation induces DCM and (2) how epigenetic remodeling reversed this process. For that, our challenges are: 1A. To decipher how aged-linked cardiac dysfunction contributes to CVD by identifying the epigenetic landscape regulating cardiac aging among species; 1B. To decode how epigenetic deregulation induces DCM by integrating clinical data and samples from DCM-transplanted patients with imaging, transcriptomic, proteomic, and functional approaches from DCM model; and, 2A. To identified systemic factors with anti-cardiomyopathic effects by systematic proteomic screenings after parabiosis and epigenome of the DCM hearts. In sum, YOUNGatHEART puts forward an ambitious but feasible and pioneering program to tackle the epigenetic hallmark in cardiac aging with the final aim (2B) of setting the molecular basis for future therapeutic interventions in CVD.

Keywords: cardiovascular disease,dilated cardiomyopathy,aging,epigenetic regulation,polycomb,bmi1
Effects of Cross-Linguistic Interactions on Perception of Speech (E-CLIPS)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Social Sciences and Humanities
Countries involved: Spain
Call: Individual Fellowships (H2020-MSCA-IF-2017, 2017)
Start date: 2019-07-01
End date: 2021-06-30
Duration (months): 24.0
Total project cost (EUR): 158121.6
EU funding (EUR): 158121.6
Participants: 1
Project status: CLOSED

Conversations often take place in noisy environments like a crowded coffee shop. In the European community, many of these conversations are among bilinguals and in a second language. Although adverse listening conditions have little impact on comprehension in one’s native language, communication can be severely affected in a bilingual’s second language. The neural systems involved in spoken language and the mechanisms that facilitate comprehension have been extensively investigated in monolinguals. However, much is unknown about the neural architecture that supports language comprehension in bilinguals. Bilinguals have, not one, but two systems that map sound-to-meaning. Here we investigate how the two languages interact with one another and how that affects access to meaning under naturalistic listening conditions. A combination of complementary methodologies — behavior, fMRI, and ERP/EEG — will be used to characterize the nature, locus, and temporal dynamics of mapping sound-to-meaning in bilinguals. The research location also provides a rare opportunity to compare two unique balanced bilingual populations that share one common language, Basque; the two groups of bilinguals differ in the degree to which their first (Spanish or French) languages overlap in their sound structure with Basque. The project aims to bridge bilingualism and speech perception research, two rapidly growing areas of study, to provide a unifying neural framework for bilingual spoken language processing. This work will provide the basis for clinical and technological advances that support language comprehension.

Keywords: flexible speech perception,semantic perceptual interactions,bilingual word recognition,feedforward and feedback interactions,top down effects,semantic context effects,semantic priming
Stroke Management through RGTA®: SMR (SMR)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: France
Call: SME instrument (H2020-SMEInst-2018-2020-2, 2018)
Start date: 2018-10-01
End date: 2023-11-30
Duration (months): 62.0
Total project cost (EUR): 3404200.0
EU funding (EUR): 2382940.0
Participants: 2
Project status: SIGNED

Stroke is the 2nd cause of death and major handicaps in industrialized countries. At present, the only available treatment for ischemic stroke are thrombolysis and thrombectomy. However, very few patients are eligible, and it is therefore absolutely urgent to find an alternative. RGTA® are synthetic polysaccharides, mimicking endogenous macro-molecules called heparan sulphates, that make up the biological networks in which our cells live and reproduce: the extracellular matrix. We have recently investigated the neuroprotective potential of a novel specific RGTA® (OTR4132) at the preclinical level using a rodent model of transient focal cerebral ischemia The i.v. administration of OTR4132-MD elicited a reduction of 39,6% of the volume of infarction at 48 hours following the insult. Interestingly, this RGTA®-induced reduction of brain damage persisted up to the chronic stage and RGTA®-treated animals showed a significant improvement of functional recovery (motor and sensorial) when compared to control animals. Translational stroke studies in rodent models have thus already demonstrated the beneficial effects of RGTA® in acute phase and, following additional preclinical studies in an independent laboratory, the project will be ready for next stages of its route to market introduction, including clinical validation and product registration. The objective of the SMR project is to translate experimental findings into medical innovation, leading to a quick benefit for stroke patients. Positive outcomes of the project will lead rapidly to the EU registration of OTR4132-MD injectable solution as a medical device or a drug and to its market introduction in Europe for the stroke indication.

Keywords: regenerative medecine,stroke,neuroprotection,cell therapy
DISPERSIVE GENOMES: Epigenetic potential as mediator of phenotypic plasticity and natal dispersal (GENESPERSIVE)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Environment and Geosciences
Countries involved: Spain
Call: Individual Fellowships (H2020-MSCA-IF-2020, 2020)
Start date: 2022-09-01
End date: 2024-12-21
Duration (months): 24.0
Total project cost (EUR): 160932.48
EU funding (EUR): 160932.48
Participants: 1
Project status: SIGNED

In an increasingly changing world, organisms need to adjust to environmental fluctuations, and life-history traits should evolve towards maximizing fitness in the face of this variability. Natal dispersal - the movement between the place of birth and first breeding - is a particularly relevant life history trait, and a pivotal decision that will determine fitness prospects, population dynamics and species distributions. Despite previous evidence that not all phenotypes are equally likely to disperse, the mechanistic underpinnings driving variation in natal dispersal remain poorly investigated. Epigenetic mechanisms – changes in gene expression that do not involve changes in the DNA sequence – enable more rapid and plastic phenotypic responses than are possible via genetic change, and individual genomes may differ in their capacity to respond epigenetically – i.e. epigenetic potential. A high capacity for epigenetically-induced phenotypic plasticity may be a requirement for dispersing individuals to successfully establish in novel environments, and I predict that individuals with higher natal dispersal propensity will show greater epigenetic potential. To test this, I will use a 37-year dataset from a wild bird population and combine analysis of historical samples, field experiments and cutting-edge epigenetic techniques. I will address this question at broad spatial and temporal scales, including long-term individual data and samples from multiple Eurasian populations to track past colonization and current expansion events. I will be amongst the first providing mechanistic insights of dispersal behavior, a fundamental part of accurately predicting species responses to climate and anthropic changes. I previously focused on studying physiological mechanisms driving phenotypic responses to environmental challenges, and I with this project I will take this expertise further into connecting molecular mechanisms, evolutionary processes and broad scale population dynamics.

Keywords: epigenetic potential,phenotypic plasticity,natal dispersal,bird
A Probe of the Periodic Elements for Life in the Sea (APPELS)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Earth system science
Panel description: Physical geography, geology, geophysics, atmospheric sciences, oceanography, climatology, cryology, ecology, global environmental change, biogeochemical cycles, natural resources management
Countries involved: United Kingdom
Call: ERC Consolidator Grant (ERC-2015-CoG, 2015)
Start date: 2016-06-01
End date: 2022-11-30
Duration (months): 78.0
Total project cost (EUR): 2000000.0
EU funding (EUR): 2000000.0
Participants: 1
Project status: SIGNED

Chemical elements are the building blocks of life. The major elements, C, H. O, N, P, S are easily recognised as essential nutrients, but their use by life relies on metalloproteins. The identity of the metal centres of these metalloproteins and even the broader palette of trace elements fundamental to life are remarkably poorly known. Whole genomes remain opaque to decoding of this bioinorganic dimension, and optimal trace element concentrations for physiological function. Defining the elemental requirements for maximum growth rate of photosynthesising phytoplankton in the ocean, is critical to understanding Earth's climate. Although microscopic in stature, phytoplankton exert a gigantic influence on the biological pumping of carbon from the atmosphere to the deep ocean. Yet their metal requirements are poorly constrained, being inferred from cellular quotas and "nutrient-like" ocean metal distributions, susceptible to ambiguity between mistaken cellular uptake and use. APPELS will undertake a two-pronged approach to define the modern marine metallome/metalloproteome. I will explore the expanse of the periodic table for novel required elements by growing phytoplankton, representative of the broadest chemotypes, in manipulated media, to delineate optimal conditions for growth whereby any limitation at lowered concentrations implies use. The second prong uses cutting-edge techniques that unite methods from proteomics with geochemical mass-spectrometry to allow both metals and their associated proteins to be examined comprehensively. APPELS will transform our understanding of the essential elements in the ocean and how the biological pump of carbon is geared to ocean chemistry in an evolving world. More broadly, APPELS will provide a step change in documented protein-metal binding centres, with implications for discovery of novel biochemical pathways, and optimal nutrition.

Keywords: phytoplankton,carbon cycle,biological pump,metallomics,essential elements,bioinorganic chemistry,metalloproteins